Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to High-Intensity Statin Therapy

Next Previous
X
Search
Trial Profile

A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to High-Intensity Statin Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obicetrapib (Primary) ; HMG-CoA reductase inhibitors
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Acronyms ROSE
  • Sponsors NewAmsterdam Pharma

    • Most Recent Events

    • 21 May 2024 According to NewAmsterdam Pharma media release, data from the study will be presented at the European Atherosclerosis Society (EAS) 92nd Congress and the National Lipid Association (NLA) 2024 Scientific Sessions, taking place on May 26 -29 in Lyon, France and May 30 June 2 in Las Vegas, Nevada.
    • 11 Aug 2022 According to a NewAmsterdam Pharma media release, results from this study were published in the peer-reviewed journal, Nature Medicine.
    • 11 Aug 2022 Results published in the NewAmsterdam Pharma media release,

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top